Zobrazeno 1 - 4
of 4
pro vyhledávání: '"M. E. Arcila"'
Autor:
Ying Taur, Lauren Bohannon, Sean M. Devlin, Daniela Weber, M. A. Jamal, Koji Hayasaka, Melissa D. Docampo, Emily Fontana, D. Pham, Nelson J. Chao, Daigo Hashimoto, Jonathan U. Peled, R. Pinedo, Meagan V. Lew, Joao B. Xavier, Eric G. Pamer, C. Scheid, Anna Staffas, C. K. Stein-Thoeringer, Sergio Giralt, D. Bajic, Molly Maloy, Luigi A Amoretti, G. Armijo, Yusuke Shono, Anthony D. Sung, A. Lazrak, Yuta Hasegawa, Roberta J. Wright, Alessandro Pastore, M. Burgos da Silva, A. Tsakmaklis, J. B. Slingerland, Robert R. Jenq, Ernst Holler, M. E. Arcila, Doris M. Ponce, Kate A. Markey, Annelie Clurman, Julia A. Messina, Antonio L.C. Gomes, Ann E. Slingerland, Eric R. Littmann, M.R.M. van den Brink, Amy Bush, Sebastien Monette, Miguel-Angel Perales, Takanori Teshima, Amanda J. Pickard, Kristi Romero, M. J. G. T. Vehreschild, K. B. Nichols, Justin R. Cross
Publikováno v:
Science
Lactose can fuel GVHD Allogeneic hematopoietic cell transplantation (allo-HCT) is used to treat certain hematopoietic malignancies, but patients have a risk of developing graft-versus-host disease (GVHD). Stein-Thoeringer et al. performed a large-sca
Autor:
J, Naidoo, C S, Sima, K, Rodriguez, N, Busby, K, Nafa, M, Ladanyi, G J, Riely, M G, Kris, M E, Arcila, H A, Yu
Publikováno v:
Cancer. 121(18)
Epidermal growth factor receptor (EGFR) exon 20 insertions (exon20ins) represent approximately 10% of EGFR-mutant lung adenocarcinomas, and are associated with resistance to EGFR tyrosine kinase inhibitors (TKIs). Clinical outcomes in comparison with
Publikováno v:
Journal of neurobiology. 33(2)
Morphology and functional capacity of homotopically transplanted extensor digitorum longus muscles (EDL) of adult SCID mice that received 1 x 10(6) myoblasts [stably transfected to express nuclear localizing beta-galactosidase under the control of th
Autor:
Xiao W; Hematopathology Diagnostic Service, Department of Pathology., Bharadwaj M; Center for Hematologic Malignancies., Levine M; Center for Hematologic Malignancies., Farnhoud N; Center for Hematologic Malignancies., Pastore F; Human Oncology and Pathogenesis Program., Getta BM; Bone Marrow Transplant Service, Department of Medicine., Hultquist A; Human Oncology and Pathogenesis Program., Famulare C; Center for Hematologic Malignancies., Medina JS; Center for Hematologic Malignancies., Patel MA; Center for Hematologic Malignancies., Gao Q; Hematopathology Diagnostic Service, Department of Pathology., Lewis N; Hematopathology Diagnostic Service, Department of Pathology., Pichardo J; Hematopathology Diagnostic Service, Department of Pathology., Baik J; Hematopathology Diagnostic Service, Department of Pathology., Shaffer B; Bone Marrow Transplant Service, Department of Medicine., Giralt S; Bone Marrow Transplant Service, Department of Medicine., Rampal R; Leukemia Service, Department of Medicine., Devlin S; Epidemiology and Biostatistics., Cimera R; Cytogenetic Laboratory, Department of Pathology, and., Zhang Y; Cytogenetic Laboratory, Department of Pathology, and., E Arcila M; Molecular Diagnostic Service, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY., Papaemmanuil E; Center for Hematologic Malignancies.; Epidemiology and Biostatistics., Levine RL; Center for Hematologic Malignancies.; Human Oncology and Pathogenesis Program.; Leukemia Service, Department of Medicine., Roshal M; Hematopathology Diagnostic Service, Department of Pathology.
Publikováno v:
Blood advances [Blood Adv] 2018 Dec 11; Vol. 2 (23), pp. 3526-3539.